Global Cord Blood (NYSE:CO) Coverage Initiated at started coverage on shares of Global Cord Blood (NYSE:COFree Report) in a research report sent to investors on Thursday. The firm issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Trading Up 16.3 %

Shares of CO opened at $2.00 on Thursday. The stock has a fifty day moving average price of $1.30 and a 200-day moving average price of $1.27. Global Cord Blood has a 12 month low of $2.03 and a 12 month high of $5.50. The firm has a market cap of $243.10 million, a PE ratio of 3.13 and a beta of 0.16.

Institutional Trading of Global Cord Blood

Institutional investors have recently bought and sold shares of the stock. Moneta Group Investment Advisors LLC increased its position in shares of Global Cord Blood by 99,844.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock valued at $77,957,000 after acquiring an additional 26,067,412 shares during the period. Natixis Advisors L.P. raised its stake in shares of Global Cord Blood by 5.6% in the second quarter. Natixis Advisors L.P. now owns 199,880 shares of the medical research company’s stock worth $592,000 after purchasing an additional 10,550 shares during the last quarter. Finally, Northern Trust Corp acquired a new stake in shares of Global Cord Blood during the second quarter worth about $96,000.

Global Cord Blood Company Profile

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Read More

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with's FREE daily email newsletter.